Keytruda receives Positive EU CHMP Opinion in combination with chemotherapy as first-line treatment for certain patients with esophageal cancer or HER2- GEJ adenocarcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Committee for Medicinal Products for Human Use of the European Medicines Agency as adopted a positive opinion recommending approval of Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10). 

The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union, and a final decision is expected in the second quarter of 2021.

Keytruda is sponsored by Merck. 

The positive CHMP opinion is based on results from the pivotal phase III KEYNOTE-590 trial, in which Keytruda plus 5-fluorouracil (5-FU) and cisplatin demonstrated significant improvements in overall survival and progression-free survival compared with 5-FU and cisplatin alone in patients regardless of histology or PD-L1 expression status. 

Keytruda plus 5-FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; p<0.0001) versus 5-FU and cisplatin alone.

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login